SG Americas Securities LLC purchased a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 8,013 shares of the company’s stock, valued at approximately $1,580,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of AZNCF. Hughes Financial Services LLC acquired a new position in AstraZeneca in the fourth quarter worth $34,000. Fairscale Capital LLC bought a new stake in shares of AstraZeneca during the fourth quarter worth $37,000. Mascoma Wealth Management LLC acquired a new stake in shares of AstraZeneca in the fourth quarter valued at $46,000. Aventus Investment Advisors Inc. acquired a new stake in shares of AstraZeneca in the first quarter valued at $46,000. Finally, Resources Management Corp CT ADV bought a new position in shares of AstraZeneca in the fourth quarter valued at about $61,000. 40.87% of the stock is owned by institutional investors and hedge funds.
AstraZeneca Stock Performance
Shares of OTCMKTS AZNCF opened at $187.10 on Friday. The firm’s 50-day simple moving average is $187.10 and its 200 day simple moving average is $186.46. AstraZeneca PLC has a 12-month low of $122.26 and a 12-month high of $195.00.
AstraZeneca Profile
AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.
The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.
Featured Stories
- Five stocks we like better than AstraZeneca
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
